Previous 10 | Next 10 |
Regulus Therapeutics Announces Resignation of Board Member PR Newswire SAN DIEGO , Dec. 12, 2022 /PRNewswire/ -- Regulus Therapeutics Inc . ( Nasdaq : RGLS ), a biopharmaceutical company focused on the discovery and development of innovative med...
Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations PR Newswire Additional Preclinical Promotions Round Out Scientific Leadership SAN DIEGO ...
Regulus Therapeutics, Inc. (RGLS) Q3 2022 Earnings Conference Call November 10, 2022, 17:00 ET Company Participants Crispina Calsada - CFO Jay Hagan - President, CEO & Director Denis Drygin - Chief Scientific Officer Conference Call Participants Y...
Regulus Therapeutics press release ( NASDAQ: RGLS ): Q3 GAAP EPS of -$0.50. Cash, Cash Equivalents and Marketable Securities: As of September 30, 2022, Regulus had $45.3 million in cash, cash equivalents and short-term investments. For further details see: Regulu...
Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates PR Newswire Company announced first patient dosed in its Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 in patients with Autosomal Dominant Polycystic Kidney Disease (ADP...
A California-based %Biotech firm is causing a bit of a stir during Tuesday’s action after it was announced that Canaccord Genuity initiated coverage on the micro cap with a price target of $9. Seeing that this stock closed at just $1.57 on Monday, naturally there was a shift in s...
Regulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference Call PR Newswire SAN DIEGO , Nov. 3, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery ...
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO , Nov. 2, 2022 /PRNewswire/ -- Regulu...
Regulus Therapeutics Announces Poster Presentation at ASN Kidney Week 2022 PR Newswire SAN DIEGO , Oct. 27, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative m...
3 Hot Penny Stocks to Add to Your Watchlist Now With so many penny stocks to add to your watchlist right now, how do you know which ones to pick? It’s tough to make money with penny stocks these days. Many experts are trading with a high degree of cautious optimism. The m...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...